A Blood-Based Liquid Biopsy Combined with Machine Learning for Early Lung Cancer Diagnosis
By LabMedica International staff writers Posted on 05 Oct 2021 |
![Image: The DELFI blood test identifies lung cancer using artificial intelligence to detect unique patterns in the fragmentation of DNA shed from cancer cells compared to normal profiles (Photo courtesy of Carolyn Hruban) Image: The DELFI blood test identifies lung cancer using artificial intelligence to detect unique patterns in the fragmentation of DNA shed from cancer cells compared to normal profiles (Photo courtesy of Carolyn Hruban)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2021-08-30/GMS-068B.jpg)
Image: The DELFI blood test identifies lung cancer using artificial intelligence to detect unique patterns in the fragmentation of DNA shed from cancer cells compared to normal profiles (Photo courtesy of Carolyn Hruban)
A novel liquid biopsy that collects fragments of circulating tumor DNA combined with advanced machine learning technology was able to detect over 90% of lung cancers in samples from nearly 800 individuals with and without the disease.
Investigators at Johns Hopkins Medicine (Baltimore, MD, USA) debuted the field of fragmentomics as the basis for lung cancer diagnosis. Fragmentomics studies the physical properties of circulating cell-free DNA fragments. DNA is packaged abnormally in cancer cells, resulting in abnormal fragment patterns when cancer cells die and release their DNA into the bloodstream. Cell-free DNA fragments in the blood can indicate the presence of cancer and suggest its likely location in the body.
Advanced machine learning (artificial intelligence) technology was used to compare an individual’s cell-free DNA patterns against populations with and without cancer. The technology, called DELFI (DNA evaluation of fragments for early interception), used millions of data points to identify both the presence of cancer and its tissue of origin.
For the current study, the investigators, working with colleagues in Denmark and the Netherlands, first performed genome sequencing of cell-free DNA in blood samples from 365 individuals participating in a seven-year Danish study called LUCAS. They validated the cancer detection model using the DELFI approach on an independent cohort of 385 non-cancer individuals and 46 lung cancer patients.
Results revealed that combining fragmentation features, clinical risk factors, and CEA (carcinoembryonic antigen) levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across nearly 13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy.
“It is clear that there is an urgent, unmet clinical need for development of alternative, noninvasive approaches to improve cancer screening for high-risk individuals and, ultimately, the general population,” said first author Dr. Dimitrios Mathios, a postdoctoral researcher at Johns Hopkins Medicine. “We believe that a blood test, or liquid biopsy, for lung cancer could be a good way to enhance screening efforts, because it would be easy to do, broadly accessible and cost-effective.”
A national clinical trial of the DELFI approach is being carried out by the biotech company Delfi Diagnostics (Baltimore, MD, USA). This trial is using the technique to evaluate 1,700 participants in the United States, including healthy participants, individuals with lung and other types of cancers.
The DELFI lung cancer study was published in the August 20, 2021, online edition of the journal Nature Communications.
Related Links:
Johns Hopkins Medicine
Delfi Diagnostics
Investigators at Johns Hopkins Medicine (Baltimore, MD, USA) debuted the field of fragmentomics as the basis for lung cancer diagnosis. Fragmentomics studies the physical properties of circulating cell-free DNA fragments. DNA is packaged abnormally in cancer cells, resulting in abnormal fragment patterns when cancer cells die and release their DNA into the bloodstream. Cell-free DNA fragments in the blood can indicate the presence of cancer and suggest its likely location in the body.
Advanced machine learning (artificial intelligence) technology was used to compare an individual’s cell-free DNA patterns against populations with and without cancer. The technology, called DELFI (DNA evaluation of fragments for early interception), used millions of data points to identify both the presence of cancer and its tissue of origin.
For the current study, the investigators, working with colleagues in Denmark and the Netherlands, first performed genome sequencing of cell-free DNA in blood samples from 365 individuals participating in a seven-year Danish study called LUCAS. They validated the cancer detection model using the DELFI approach on an independent cohort of 385 non-cancer individuals and 46 lung cancer patients.
Results revealed that combining fragmentation features, clinical risk factors, and CEA (carcinoembryonic antigen) levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across nearly 13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy.
“It is clear that there is an urgent, unmet clinical need for development of alternative, noninvasive approaches to improve cancer screening for high-risk individuals and, ultimately, the general population,” said first author Dr. Dimitrios Mathios, a postdoctoral researcher at Johns Hopkins Medicine. “We believe that a blood test, or liquid biopsy, for lung cancer could be a good way to enhance screening efforts, because it would be easy to do, broadly accessible and cost-effective.”
A national clinical trial of the DELFI approach is being carried out by the biotech company Delfi Diagnostics (Baltimore, MD, USA). This trial is using the technique to evaluate 1,700 participants in the United States, including healthy participants, individuals with lung and other types of cancers.
The DELFI lung cancer study was published in the August 20, 2021, online edition of the journal Nature Communications.
Related Links:
Johns Hopkins Medicine
Delfi Diagnostics
Latest Molecular Diagnostics News
- Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods
- Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
Channels
Clinical Chemistry
view channel![Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF) Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-27/98234491_m_normal_none.jpg)
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more![Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT) Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-10/MIT-Printed-Ion-01-press_0.jpg)
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more![Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University) Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-14/Spinning-Glowing (1).jpg)
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more![Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University) Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-04/ac3c04435_0004.jpg)
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreHematology
view channel![Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia) Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/C3_DBS_Website.2.jpg)
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more![Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols) Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-08/donor-testing-1.jpg)
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more![Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health) Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-20/news-7.jpg)
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more![Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health) Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-02-08/inserting-hb-variant-cartridge.jpg)
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel![Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute) Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/Surgical oncology 43 (1).jpg)
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more![Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer) Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-03/906uv0fs34hr.jpg)
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read moreMicrobiology
view channel![Image: The PA-100 AST System for rapid AMR detection has won the “Longitude Prize on AMR” (Photo courtesy of Sysmex Astrego) Image: The PA-100 AST System for rapid AMR detection has won the “Longitude Prize on AMR” (Photo courtesy of Sysmex Astrego)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-17/PA-100-diskette-device_1.jpg)
Rapid UTI Test Cuts Detection Time from 3 days to 45 Minutes
Antimicrobial Resistance (AMR), also known as antibiotic resistance or superbugs, is a silent but growing pandemic where bacteria have become resistant to lifesaving antibiotics due to decades of overuse and misuse.... Read more![Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical) Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/device-front.jpg)
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more![Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock) Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-08/shutterstock_1065839396.jpg)
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more![Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB) Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-07/ASTar_ft-1-700x494.jpg)
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read morePathology
view channel![Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock) Image: The Hairpin Duplex Enhanced Fidelity Sequencing (HiDEF-seq) could reveal the causes of mutations (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-14/shutterstock_447424987.jpg)
New Technique Reveals Earliest Signs of Genetic Mutations
Mutations are alterations in the molecular "letters" that constitute the DNA code, which serves as the blueprint for all living cells. While some of these changes may be inconsequential, others can lead... Read more![Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová) Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-13/Low-Res_jctp-23-68-g005.jpg)
New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
Lung cancer continues to be the most common cause of cancer-related deaths worldwide and ranks as the second most frequently diagnosed cancer in both men and women. The role of lung cytopathology, which... Read more![Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine) Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-12/inline_Untitled-3.jpg)
Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.... Read more![Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF) Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-11/17907939_m_normal_none_1.jpg)
Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
Scientists at Brown University (Providence, RI, USA) and the University of Michigan (Ann Arbor, MI, USA) have created a groundbreaking computational technique to examine complex tissue data, potentially... Read moreTechnology
view channel![Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet) Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/plaster_custom20240529112158.jpg)
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more![Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz) Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/new-diagnostic-tool-ac.jpg)
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read moreIndustry
view channel![Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche) Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-28/download.jpg)
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more![Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF) Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-13/103048801_m_normal_none.jpg)
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more![Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter) Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-09/PR_partnership_with_Beckman_Coulter_v1_2.jpg)
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more![Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF) Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-01/130140677_m_normal_none (1)_1.jpg)